When Metal Complexes Evolve, and a Minor Species is the Most Active: the Case of Bis(Phenanthroline)Copper in the Catalysis of Glutathione Oxidation and Hydroxyl Radical Generation
Year: 2024
Type: article
Abstract: Several copper‐ligands, including 1,10‐phenanthroline (Phen), have been investigated for anticancer purposes based on their capacity to bind excess copper (Cu) in cancer tissues and form redox active complexes able to catalyse the formation of reactive oxygen species (ROS), ultimately leading to oxidative stress and cell death. Glutathione (GSH) is a critical compound as it is highly concentrated intracellularly and can reduce and dissociate copper(II) from the ligand forming poorly redox‐active copper(I)‐thiolate clusters. Here we report that Cu‐Phen 2 speciation evolves in physiologically relevant GSH concentrations. Experimental and computational experiments suggest that at pH 7.4 mostly copper(I)‐GSH clusters are formed, but a minor species of copper(I) bound to one Phen and forming ternary complexes with GSH (GS−Cu‐Phen) is the redox active species, oxidizing quite efficiently GSH to GSSG and forming HO⋅ radicals. This minor active species becomes more populated at lower pH, such as typical lysosomal pH 5, resulting in faster GSH oxidation and HO⋅ production. Consistently, cell culture studies showed lower toxicity of Cu‐Phen 2 upon inhibition of lysosomal acidification. Overall, this study underscores that sub‐cellular localisation can considerably influence the speciation of Cu‐based drugs and that minor species can be the most redox‐ and biologically‐active.
Source: Angewandte Chemie
Institutions: Centre National de la Recherche Scientifique, Institut de Chimie de Strasbourg, Laboratoire de Chimie de Coordination, Université de Strasbourg, University of Calabria, Comprehensive Cancer Center Vienna, Medical University of Vienna, University of Rome Tor Vergata, Observatoire des Sciences de l'Univers de Grenoble, Université Grenoble Alpes, Institut Universitaire de France
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $5,250
Funders: Equipex, Agence Nationale de la Recherche
OpenAlex ID: W4403140493
